Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the market grown in recent years?

The market size for vutrisiran has experienced a swift expansion in the last few years. It is forecasted to increase from $0.60 billion in 2024 to $0.68 billion in 2025, yielding a compound annual growth rate (CAGR) of 12.8%. Factors contributing to the growth during the historical period include heightened knowledge of hereditary transthyretin amyloidosis, an increase in clinical trials, escalating healthcare expenditure, an increased preference among patients for non-invasive modes of administration, and a rise in genetic disorders.

How is the market size expected to evolve during the forecast period?

In the coming years, the vutrisiran market is projected to experience a swift expansion. Forecasted to reach $1.08 billion by 2029, the market will nurture at a compound annual growth rate (CAGR) of 12.4%. Factors contributing to this growth in the predicted period include improved healthcare accessibility, a spike in chronic disease incidence, increased expenditure in research and development, stronger emphasis on individualized medicine, and growing knowledge about illness. Influential trends to watch out for in this period entail progress in combined therapy, the shift towards targeted treatment, advancements in customized medicine, evolution in digital health technology, and breakthroughs in the field of biotechnology.

Get your market report here!

https://www.thebusinessresearchcompany.com/report/vutrisiran-global-market-report

What are the major factors driving growth in the market?

The escalation of funding towards research and development is anticipated to accelerate the progress of the vutrisiran market. Research and development involves innovation and enhancement of products, services, or methodologies via thorough inquiry and testing. The amplified allocation towards research and development is backed by government initiatives, increased healthcare and pharmaceutical requirements, sustainability, and issues related to the environment. The provision for research and development enables pharmaceutical businesses to carry out clinical trials, thereby verifying the long-term advantages and safety of the drug and facilitating wider regulatory approvals. Advancements in RNA interference (RNAi) technology enhance the accuracy of the drug, minimize side effects, and promote patient acceptance. For example, in December 2023, data from Eurostat—a statistical institution based in Luxembourg and serving the European Union—indicated that the European Union’s research and development expenditure saw an increment to €352 billion ($384.42 billion) in 2022, a rise of 6.34% from the €331 billion ($361.48 billion) spent in the preceding year. Hence, the amplified funding for research and development is fortifying the progress of the vutrisiran market.

What are the market segments in the industry?

The vutrisiran market covered in this report is segmented –

1) By Drug Class: Antisense Oligonucleotide, Nucleic Acids, Nucleotide, Nucleoside, Other Drug Classes

2) By Route Of Administration: Oral, Injectable, Subcutaneous

3) By Patient Demographics: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Antisense Oligonucleotide: Single-Stranded Antisense Oligonucleotides, Double-Stranded Antisense Oligonucleotides

2) By Nucleic Acids: DNA-based Nucleic Acids, RNA-based Nucleic Acids

3) By Nucleotide: Purine Nucleotides, Pyrimidine Nucleotides

4) By Nucleoside: Purine Nucleosides, Pyrimidine Nucleosides

5) By Other Drug Classes: Peptide-Based Drugs, Protein Therapeutics

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21320&type=smp

Which leading companies are shaping the growth of the market?

Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc

What emerging trends are influencing the growth of the market?

A significant trend observed in the vutrisiran market is the intensified efforts towards creating novel therapies, such as subcutaneous RNAi treatments. These potential game-changers aim to offer more accessible and less regular dosages for dealing with hereditary transthyretin-mediated (hATTR) amyloidosis. The subcutaneous RNAi treatments, administered through an under-the-skin injection, are designed for lasting release. This ensures a steady supply of the drug, thereby enhancing compliance and providing greater convenience to patients dealing with polyneuropathy related to hATTR amyloidosis. For instance, Alnylam Pharmaceuticals, an American biopharmaceutical corporation, reported in June 2022 that the Food and Drug Administration (FDA) has sanctioned the usage of vutrisiran (AMVUTTRA) for treating polyneuropathy in adults affected by hATTR amyloidosis. This important approval has resulted in a substantial improvement in neuropathy symptoms and a check on the disease’s progression. According to the HELIOS-A Phase 3 trial, over half of the patients witnessed a reversal or stoppage of disease symptoms. AMVUTTRA boasts of an encouraging safety record, with no drug-related discontinuations or fatalities, and a dosage protocol that potentially encourages patient obedience.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21320

Which geographic areas are influencing the growth of the market?

North America was the largest region in the vutrisiran market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Hepatitis B Virus (HBV) Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Viral Hepatitis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Hepatitis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: